{"nctId":"NCT02260804","briefTitle":"To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma","startDateStruct":{"date":"2015-11-09","type":"ACTUAL"},"conditions":["Follicular Lymphoma"],"count":258,"armGroups":[{"label":"CT-P10","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P10"]},{"label":"Rituxan","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Rituxan"]}],"interventions":[{"name":"CT-P10","otherNames":[]},{"name":"Rituxan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of low tumour burden, CD20+ follicular lymphoma\n* Ann Arbor Stage II, III or IV\n\nExclusion Criteria:\n\n* Has receive rituximab\n* Allergies or hypersensitivity to murine, chimeric, human or humanised proteins\n* Previous treatment for NHL\n* Any malignancy\n* Current or recent treatment with any other investigational medicinal product or device\n* pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Efficacy Endpoint - Overall Response Rate by 7 Months","description":"ORR was defined as the proportion of patients with the best response of complete response (CR), unconfirmed CR (CRu), or partial response (PR) by central review.\n\nPer 1999 IWG criteria, the disease status was assessed by using contrasted CT and/or MRI, and CR, CRu, and PR were defined as followings; CR=Disappearance of all clinical/radiographic evidence of disease: regression of lymph nodes to normal size, absence of B-symptoms, bone marrow involvement, and organomegaly, and normal LDH level; CRu=Regression of measurable disease: \\>75% decrease in SPD of target lesions and in each target lesions. no increase in the size of non-target lesions, neither new lesion nor organomegaly measured; PR=Regression of measurable disease: ≥50% decrease in SPD of target lesions and no evidence of disease progression.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Endpoint - ORR Over the Study Period","description":"ORR was defined as the proportion of patients with the best response of complete response (CR), unconfirmed CR (CRu), or partial response (PR).\n\nPer 1999 IWG criteria, the disease status was assessed by using contrasted CT and/or MRI, and CR, CRu, and PR were defined as followings; CR=Disappearance of all clinical/radiographic evidence of disease: regression of lymph nodes to normal size, absence of B-symptoms, bone marrow involvement, and organomegaly, and normal LDH level; CRu=Regression of measurable disease: \\>75% decrease in SPD of target lesions and in each target lesions. no increase in the size of non-target lesions, neither new lesion nor organomegaly measured; PR=Regression of measurable disease: ≥50% decrease in SPD of target lesions and no evidence of disease progression.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary PD Endpoint - B-cell Kinetics (B-cell Depletion and Recovery)","description":"B-cell kinetics were demonstrated by median values of B-cell counts. Any values below the LLoQ were set as LLoQ which was 20 cells/μL.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"120.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary PK Endpoints - Cmax","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212.86","spread":"50.64"},{"groupId":"OG001","value":"217.38","spread":"56.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"283.35","spread":"53.84"},{"groupId":"OG001","value":"285.98","spread":"62.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"327.32","spread":"71.05"},{"groupId":"OG001","value":"341.59","spread":"77.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"373.46","spread":"70.50"},{"groupId":"OG001","value":"383.05","spread":"83.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"256.97","spread":"65.61"},{"groupId":"OG001","value":"265.03","spread":"53.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239.70","spread":"65.72"},{"groupId":"OG001","value":"249.86","spread":"69.02"}]}]}]},{"type":"SECONDARY","title":"Secondary PK Endpoints - Ctrough","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.66","spread":"24.88"},{"groupId":"OG001","value":"72.94","spread":"40.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113.23","spread":"34.60"},{"groupId":"OG001","value":"120.92","spread":"36.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.53","spread":"43.65"},{"groupId":"OG001","value":"161.80","spread":"43.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.78","spread":"33.58"},{"groupId":"OG001","value":"31.38","spread":"19.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.68","spread":"37.22"},{"groupId":"OG001","value":"21.35","spread":"20.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.96","spread":"9.61"},{"groupId":"OG001","value":"18.37","spread":"10.86"}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Endpoint - Progression-free Survival (PFS)","description":"PFS was defined as the interval between randomization and disease progression/relapse by IWG 1999 (at least a 50% increase of any single nodal after smallest decrease) or death from any cause, whichever occurred first. Locally reviewed data was used for the secondary efficacy analyses.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null},{"groupId":"OG001","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":null},{"groupId":"OG001","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":null},{"groupId":"OG001","value":"0.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Endpoint - Overall Survival (OS)","description":"Overall survival was defined as the interval between randomization and death from any cause. Locally reviewed data was used for the secondary efficacy analyses.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Endpoint - Time-to Progression (TTP)","description":"Time to progression was defined as the interval between randomization and disease progression/relapse by IWG 1999 (at least a 50% increase of any single nodal after smallest decrease) or death as a result of lymphoma, whichever occurred first. Locally reviewed data was used for the secondary efficacy analyses.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":null},{"groupId":"OG001","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null},{"groupId":"OG001","value":"0.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.68","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":130},"commonTop":["Infusion related reaction","Upper respiratory tract infection","Fatigue","Urinary tract infection","Cough"]}}}